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PPeripheral Vascular Disease
Elevated Levels of Inflammation,
D-Dimer, and Homocysteine Are Associated
With Adverse Calf Muscle Characteristics and
Reduced Calf Strength in Peripheral Arterial Disease
Mary M. McDermott, MD,*† Luigi Ferrucci, MD, PHD,‡ Jack M. Guralnik, MD, PHD,§
Lu Tian, SCD,† David Green, MD, PHD,* Kiang Liu, PHD,† Jin Tan, MS,† Yihua Liao, MS,†
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Frederick Hoff, MD,** Michael H. Criqui, MD, MPH††
Chicago and Evanston, Illinois; Bethesda, Maryland; Boston, Massachusetts; and San Diego, California
Objectives This study determined whether increased levels of inflammatory blood markers, D-dimer, and homocysteine
were associated with smaller calf skeletal muscle area, increased calf muscle percent fat, reduced calf muscle
density, and poorer calf strength in persons with lower extremity peripheral arterial disease (PAD).
Background Elevated levels of inflammatory markers and D-dimer are associated with greater functional impairment and
functional decline in persons with PAD. Mechanisms of these associations are unknown.
Methods Participants were 423 persons with PAD. Calf muscle area, percent fat, and density were measured with com-
puted tomography. Physical activity levels were measured objectively over 7 days with the Caltrac (Muscle Dy-
namics Fitness Network, Inc., Rocklin, California) vertical accelerometer. Isometric plantarflexion strength was
measured. Analyses were adjusted for age, gender, race, comorbidities, the ankle-brachial index, and other po-
tential confounders.
Results Higher levels of D-dimer (p  0.014), C-reactive protein (CRP) (p  0.002), interleukin (IL)-6 (p  0.001), and
soluble vascular cellular adhesion molecule (sVCAM)-1 (p  0.008) were associated with smaller calf muscle
area. Higher sVCAM-1 (p  0.004) and IL-6 (p  0.017) were associated with higher calf muscle percent fat.
Higher D-dimer (p  0.001), sVCAM-1 (p  0.001), and homocysteine (p  0.014) were associated with lower
calf muscle density. These associations were generally unchanged after additional adjustment for physical activ-
ity. Higher sVCAM-1 (p  0.013) was associated with lower calf strength.
Conclusions These data show, for the first time, that higher levels of inflammation, D-dimer, and homocysteine are associ-
ated with more adverse calf muscle characteristics in persons with PAD. These associations may contribute to
previously established associations between elevated biomarkers and functional impairment and functional de-
cline in PAD. (J Am Coll Cardiol 2007;50:897–905) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.017s
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Ahronic inflammation has been proposed as a biologic
echanism underlying aging-related functional decline. An
nflammatory state characterized by increased levels of
nflammatory cytokines and markers may contribute to
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Blood Markers and Calf Characteristics August 28, 2007:897–905without PAD (6–8). We previ-
ously reported (9) that increased
levels of D-dimer and C-reactive
protein (CRP) are associated
with poorer lower extremity
functional performance in per-
sons with PAD, independent of
confounders. Elevated levels of
inflammation and D-dimer are
associated with faster rates of
functional decline in persons
with PAD (10). Mechanisms of
these associations are unclear.
Therefore, we studied associa-
tions of elevated levels of inflam-
matory blood markers with calf
skeletal muscle characteristics
and leg strength in persons with
PAD. D-dimer and homocys-
teine were also studied. We stud-
ied D-dimer because it is an end
product of fibrinolysis and may
romote the inflammatory cascade by activating neutrophils
nd monocytes, inducing secretion of inflammatory cyto-
ines (including interleukin [IL]-6), and promoting hepatic
ynthesis of acute-phase proteins (11–14). We studied
omocysteine because it may contribute to skeletal muscle
eakness and atrophy by affecting the ability of cells to
egenerate and respond to trophic stimuli (15,16). Calf
uscle characteristics studied were calf muscle area, calf
uscle percent fat, and calf muscle density. Calf muscle
ensity is a measure of muscle fiber number per unit area
nd may be a measure of muscle quality. We hypothesized
hat higher levels of each blood marker would be associated
ith smaller muscle area, higher calf muscle percent fat,
ower calf muscle density, and lower calf muscle strength in
ersons with PAD. To determine whether significant asso-
iations of blood markers with strength were specific to the
alf muscle, we also studied associations between blood
arkers with grip strength.
ethods
articipant identification. The protocol was approved by
he Institutional Review Boards of Northwestern University
einberg School of Medicine and Catholic Health Partners
ospitals. Participants gave informed consent. Participants
ncluded persons with PAD attending their fourth annual
ollow-up visit in the WALCS (Walking and Leg Circula-
ion Study) (8,17) and newly identified PAD participants
or the present study (WALCS II). In both WALCS and
ALCS II, PAD participants were identified consecutively
rom among patients diagnosed with PAD in 3 Chicago-
rea noninvasive vascular laboratories. Data were collected
etween November 2002 and May 2004. Because partici-
Abbreviations
and Acronyms
ABI  ankle-brachial index
BMI  body mass index
CRP  C-reactive protein
CT  computed
tomography
ELISA  enzyme-linked
immunosorbent assay
HDL  high-density
lipoprotein
IL  interleukin
PAD  peripheral arterial
disease
sICAM-1  soluble
intracellular adhesion
molecule
sVCAM-1  soluble
vascular cellular adhesion
moleculeants in the original WALCS cohort were age 59 and older ct the time of this data collection, an inclusion criterion for
ewly identified participants was age 59 or older.
Of 238 PAD participants returning for their fourth
nnual follow-up visit for the WALCS, 214 underwent
omputed tomography (CT) scanning and were included in
he present analyses. An additional 240 participants with
AD were newly identified for WALCS II and underwent
T scanning. Of these, 202 (85%) from WALCS and 221
92%) of those newly identified underwent blood draw at
heir visit and were eligible for the present study.
xclusion criteria. Peripheral arterial disease was defined
s ankle-brachial index (ABI) 0.90 (17–20). Patients with
ecent major surgery were excluded. At the time of enroll-
ent for both WALCS and WALCS II, the following
xclusion criteria were applied. Patients with dementia were
xcluded because of their inability to answer questions
ccurately. Nursing home residents, wheelchair-bound pa-
ients, and patients with foot or leg amputations were
xcluded because they had severely impaired functioning.
on–English-speaking patients were excluded because in-
estigators were not fluent in non-English languages.
BI measurement. The ABI was measured using estab-
ished methods (8,17–20). After participants rested supine
or 5 min, a hand-held Doppler probe (Nicolet Vascular
ocket Dop II, Golden, Colorado) was used to measure
ystolic pressures in the right brachial artery, right dorsalis
edis and posterior tibial arteries, left dorsalis pedis and
osterior tibial arteries, and left brachial artery. Each pres-
ure was measured twice: in the order listed and then in
everse order. The ABI was calculated in each leg by
ividing average pressures in each leg by the average of the
brachial pressures (17,20). Average brachial pressures in
he arm with highest pressure were used when 1 brachial
ressure was higher than the opposite brachial pressure in
oth measurement sets and the 2 brachial pressures differed
y 10 or more mm Hg in at least 1 measurement set,
ecause in such cases subclavian stenosis was possible (21).
owest leg ABI was used in analyses.
easuring calf muscle characteristics. Using a CT scan-
er (LightSpeed, General Electric Medical Systems,
aukesha, Wisconsin), we obtained a 2.5-mm cross-
ectional image of the calves at 66.7% of the distance from
he distal to the proximal tibia (22). BonAlyse software
BonAlyse Ltd., Jyvaskyla, Finland) was used to measure
haracteristics of muscle, as follows. The muscle outline was
raced manually and excluded subcutaneous fat and bone.
hen measuring muscle area, the BonAlyse software quan-
ifies voxels within a range corresponding to muscle density
9 to 271 mg/cm3) and excludes voxels corresponding to fat
ensity (270 to 8 mg/cm3). Intramuscular fat is quantified
y summing voxels corresponding to fat within muscle
issue. Muscle density measures the amount of muscle per
olume, within the range corresponding to muscle (9 to 271
g/cm3), and is a measure of muscle quality. Previousadaver studies (23) demonstrate that these methods pro-
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August 28, 2007:897–905 Blood Markers and Calf Characteristicside an estimate of muscle area that is highly correlated with
irect anatomic measures.
sometric leg strength. Leg strength was measured using a
omputer-linked strength chair (Good Strength Chair,
etitur Oy, Jyvasklya, Finland) (24). This strength chair
as developed for measurement of isometric strength.
ransducers were placed for measurement of hand grip and
nkle extension. Data are collected over 6 s, and results are
lectronically collected by the computer. Strength measure-
ents using the Good Strength Chair have high test-retest
eliability (0.88 to 0.96) (24). Maximum strength was used
n analyses.
lood marker levels. Blood specimens were collected at
he same study visit at which leg strength and muscle
haracteristics were measured. Blood specimens were stored
t 70°C until the time of measurement. Interleukin-6 was
easured by an ultrasensitive enzyme-linked immunosor-
ent assay from R & D Systems (Minneapolis, Minnesota).
he assay has a sensitivity of 0.094 pg/ml. Enzyme-linked
mmunosorbent assays (ELISA) from R & D Systems were
sed to measure soluble intracellular adhesion molecule
sICAM)-1 and soluble vascular cellular adhesion molecule
sVCAM)-1. An Asserachrom D-Di kit (Diagnostica
tago, Parsippany, New Jersey) was used to measure fibrin
-dimer using an ELISA procedure. The Asserachrom
-Di kit has a lower detection limit of 5 ng/ml. Concen-
rations of high-sensitivity C-reactive protein were deter-
ined using an immunoturbidimetric assay on the Hitachi
17 analyzer (Roche Diagnostics, Indianapolis, Indiana), using
eagents and calibrators from Denka Seiken (Niigata, Japan).
his assay has a sensitivity of 0.003 mg/dl. The concentration
f homocysteine was determined using an enzymatic assay on
he Hitachi 917 analyzer (Roche Diagnostics), using reagents
nd calibrators from Catch Inc. (Seattle, Washington).
otal cholesterol and high-density lipoprotein levels. Total
holesterol levels were measured using enzymatic reaction
ith peroxidase/phenol-4-aminoiphenazone indicator reac-
ion (25). High-density lipoprotein (HDL) cholesterol was
easured using a direct enzymatic colorimetric assay (26).
ccelerometer-measured physical activity. Physical activ-
ty was measured objectively and continuously over seven
ays using a vertical accelerometer (Caltrac, Muscle Dy-
amics Fitness Network, Inc., Rocklin, California) (27–31).
fter 7 days, participants reported the number of activity
nits displayed on the accelerometer by telephone to inves-
igators and returned their accelerometer by mail. We
rogrammed the accelerometer identically for all partici-
ants, allowing us to compare physical activity levels be-
ween participants, irrespective of individual variation in
ge, weight, height, and gender (27–31). Programmed in
his way, the accelerometers measured “activity units” (27–
1). The validity of the Caltrac accelerometer for measuring
hysical activity in patients with PAD has been demon-
trated (27–31). In one study, there were no differences in
ccelerometer scores between persons with and without
AD over a fixed distance of 800 ft. However, over 7 days sAD participants had substantially lower Caltrac-assessed
ctivity than non-PAD participants (28).
Fifty-nine percent of participants with PAD who were
ligible for this study wore a Caltrac monitor for 7 days.
ystematic data on reasons that some participants did not
ear monitors were not collected. Some participants refused
o wear monitors, others wore monitors but did not return
hem and could not be reached at 7-day follow-up, some
articipants’ monitors malfunctioned, and, in some in-
tances, no monitors were available.
eg symptoms. Leg symptoms were classified into 1 of 5
roups using the San Diego Claudication Questionnaire
17,32): 1) intermittent claudication; 2) leg pain on exertion
nd rest; 3) atypical exertional leg pain/carry on; 4) atypical
xertional leg pain/stop; or 5) asymptomatic.
omorbidities. Algorithms developed for the Women’s
ealth and Aging Study and the Cardiovascular Health
tudy were used to document comorbidities, combining
ata from patient report, physical examination, medical
ecord review, medications, laboratory values, and a primary
are physician questionnaire (33). Comorbidities assessed
ere angina, diabetes mellitus, myocardial infarction,
troke, heart failure, pulmonary disease, cancer, spinal ste-
osis, and disk disease. American College of Rheumatology
riteria were used to adjudicate knee and hip osteoarthritis
34,35). History of hypertension was based on patient report
f physician-diagnosed hypertension or a physician’s indi-
ation of hypertension on the primary care physician
uestionnaire.
ther measures. Height and weight were measured at the
tudy visit. Body mass index (BMI) was calculated as weight
kg)/(height [m])2. Cigarette smoking history was based on
elf-report.
tatistical analyses. Associations between quartiles of each
lood factor and calf muscle characteristics (muscle area,
uscle percent fat, and muscle density) as well as strength
utcomes were evaluated using analyses of covariance and
tatistical tests for trend, adjusting for age, gender, race,
igarette smoking, BMI, leg symptoms, recruitment cohort
original WALCS vs. newly identified), hypertension, total
holesterol, HDL cholesterol, and comorbidities. Tibia
ength was included as a covariate for analyses of calf muscle
rea because a previous study (36) shows that greater tibia
ength is associated with greater calf muscle area. Statin use
as included as a covariate for analyses of CRP because
tatin use can lower CRP values. These analyses were next
epeated within the subset of participants with Caltrac
hysical activity data, with and without adjustment for
hysical activity. Significant associations between blood
arkers and plantarflexion strength were repeated with
dditional adjustment for muscle characteristics. This al-
owed us to determine whether muscle characteristics might
e in the causal pathway of associations between elevated
lood markers and lower plantarflexion strength. We con-
idered p  0.05 as the threshold for statistical significance.
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Blood Markers and Calf Characteristics August 28, 2007:897–905ll statistical analyses were performed using SAS Statistical
oftware version 9.0 (SAS Inc., Cary, North Carolina).
esults
he average age of the 423 PAD participants was 74.9 
.2 years. Forty-six percent were women and 16.6% were
frican American. The average ABI was 0.63  0.01.
mong participants, 32.1% had diabetes, 16.1% were cur-
ent smokers, and 57.4% had other clinically evident car-
iovascular disease.
There were no significant differences in age, gender, race,
BI, BMI, prevalence of diabetes mellitus, strength mea-
Figure 1 Associations Between Blood Marker Quartiles
and Calf Muscle Area in Participants With PAD
Data are adjusted for age, gender, race, cigarette smoking, body mass
index, ankle-brachial index, leg symptoms, recruitment cohort, comorbidi-
ties, statin use (C-reactive protein [CRP] only), total cholesterol, high-den-
sity lipoprotein cholesterol, hypertension, and tibia length (n  423). Red
bars  first quartile; yellow bars  second quartile; green bars  third
quartile; blue bars  fourth quartile. IL  interleukin; PAD  peripheral
arterial disease; sICAM-1  soluble intracellular adhesion molecule;
sVCAM-1  soluble vascular cellular adhesion molecule.ures, or muscle characteristics between participants withn  256) and without (n  167) Caltrac accelerometer
ata. Accelerometer wearers were average age 74.45  8.25
ears versus 75.57  8.10 years for nonwearers (p  0.170).
mong accelerometer wearers versus nonwearers, average
revalences of men were 52.2% versus 56.3% (p  0.405),
nd average ABIs were 0.63  0.15 versus 0.62  0.17
p  0.585), respectively. Average muscle area was 5,540.1 
,360 cm2 versus 5,297.53  1,445 cm2 (p  0.09), average
uscle percent fat was 10.34  11.42% versus 12.04 
3.54% (p  0.177), and average muscle density was 32.69 
.01 mg/cm3 versus 32.34  4.16 mg/cm3 (p  0.392)
mong wearers and nonwearers, respectively.
Figure 1 shows associations between quartiles of each blood
arker and calf muscle area, adjusting for age, gender, race,
Figure 2 Associations Between Blood Markers and Calf
Muscle Percent Fat in Participants With PAD
Data are adjusted for age, gender, race, cigarette smoking, body mass index,
leg symptoms, ankle-brachial index, recruitment cohort, comorbidities, total
cholesterol, high-density lipoprotein cholesterol, hypertension, and statin use
(C-reactive protein only) (n  423). Red bars  first quartile; yellow bars 
second quartile; green bars  third quartile; blue bars  fourth quartile. Abbre-
viations as in Figure 1.
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August 28, 2007:897–905 Blood Markers and Calf Characteristicsmoking, BMI, tibia length, recruitment cohort, leg symp-
oms, ABI, statin use (CRP only), total and HDL cholesterol,
nd comorbidities. Higher levels of D-dimer, CRP, IL-6, and
VCAM-1 were associated with lower calf muscle area (Fig. 1).
Figure 2 shows associations between each blood marker
nd calf muscle percent fat, adjusting for confounders.
igher levels of sVCAM-1 and IL-6 were associated
ignificantly with higher calf muscle percent fat. Associa-
ions of D-dimer with calf muscle percent fat were nearly
tatistically significant.
Figure 3 shows associations between each blood marker
nd calf muscle density, adjusting for confounders. Signif-
Figure 3 Associations Between Blood Markers and
Calf Muscle Density in Participants With PAD
Data are adjusted for age, gender, race, cigarette smoking, body mass index,
leg symptoms, ankle-brachial index, recruitment cohort, comorbidities, total
cholesterol, high-density lipoprotein cholesterol, hypertension, and statin use
(C-reactive protein only) (n  423). Red bars  first quartile; yellow bars 
second quartile; green bars  third quartile; blue bars  fourth quartile. Abbre-
viations as in Figure 1.cant associations were observed between higher levels of-dimer, sVCAM-1, and homocysteine with lower muscle
ensity, adjusting for confounders.
Significant associations were observed between higher
evels of sVCAM-1 (p trend  0.013) with poorer plantar-
exion strength, adjusting for age, gender, race, BMI,
moking, comorbidities, ABI, recruitment cohort, total and
DL cholesterol, and leg symptoms (Fig. 4). Associations
f higher homocysteine levels with poorer plantarflexion
trength were nearly statistically significant (Fig. 4). No
ignificant associations were observed between elevated
lood marker levels and grip strength (data not shown).
Table 1 shows results of associations between blood
arkers levels and calf muscle characteristics in the subset of
articipants with 7-day physical activity data, adjusting for
ge, gender, race, BMI, smoking, comorbidities, ABI,
ecruitment cohort, total and HDL cholesterol, and leg
ymptoms. Results are presented with and without addi-
ional adjustment for physical activity. Most associations
etween blood markers and calf muscle characteristics
emained statistically significant after additional adjustment
or physical activity (Table 1).
Table 2 shows associations of sVCAM-1 and homocys-
eine with plantarflexion strength after additional adjust-
ent for calf muscle area, calf muscle percent fat, and calf
uscle density. These analyses help elucidate whether calf
uscle characteristics may be in the causal pathway for
ssociations of blood marker levels with isometric strength.
he significant association of sVCAM-1 and the nearly
tatistically significant association of homocysteine with
lantarflexion strength were attenuated after additional
ombined adjustment for muscle area, muscle density, and
Figure 4 Associations Between Blood Markers and
Plantarflexion Strength in Participants With PAD
Data are adjusted for age, gender, race, cigarette smoking, body mass index,
leg symptoms, ankle-brachial index, recruitment cohort, comorbidities, total
cholesterol, high-density lipoprotein cholesterol, and statin use (C-reactive pro-
tein only) (n  403). Red bars  first quartile; yellow bars  second quartile;
green bars  third quartile; blue bars  fourth quartile. Abbreviations as in
Figure 1.
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Blood Markers and Calf Characteristics August 28, 2007:897–905uscle fat percent (Table 2). Results suggest that calf
uscle characteristics may be in the causal pathway from
levated blood marker levels to lower plantarflexion
trength.
iscussion
echanisms of functional impairment and decline in pa-
ients with PAD are not well understood. Although ele-
ated levels of inflammation and D-dimer are associated
ith greater functional impairment and faster functional
ecline in persons with PAD (9,10), mechanisms of these
ssociations are unknown.
Among 423 men and women with PAD, results reported
hysical Activity Adjusted Associations of Blood Markers With Muaracteris cs in Patients With Peripheral Arterial Disease (n  2
Table 1 Physical Activity Adjusted Associations of Blood MarkCharacteristics in Patients With Peripheral Arterial Dis
Quartile 1
Calf muscle cross-sectional area
CRP (mg/l) 0.89
Without adjustment for physical activity 5,796 (174)
With adjustment for physical activity 5,767 (171)
D-dimer (g/ml) 0.47
Without adjustment for physical activity 5,787 (174)
With adjustment for physical activity 5,766 (171)
sVCAM-1 (ng/ml) 843
Without adjustment for physical activity 5,905 (180)
With adjustment for physical activity 5,849 (178)
sICAM-1 (ng/ml) 247
Without adjustment for physical activity 5,642 (188)
With adjustment for physical activity 5,624 (185)
Interleukin-6 (pg/ml) 1.78
Without adjustment for physical activity 5,938 (166)
With adjustment for physical activity 5,915 (165)
Homocysteine (mol/l) 0.843
Without adjustment for physical activity 5,797 (174)
With adjustment for physical activity 5,792 (171)
Calf muscle percent fat
CRP (mg/l) 0.89
Without adjustment for physical activity 9.97% (1.75)
With adjustment for physical activity 10.26% (1.72)
D-dimer (g/ml) 0.47
Without adjustment for physical activity 10.22% (1.70)
With adjustment for physical activity 10.43% (1.68)
sVCAM-1 (ng/ml) 843
Without adjustment for physical activity 8.57% (1.79)
With adjustment for physical activity 9.10% (1.78)
sICAM-1 (ng/ml) 247
Without adjustment for physical activity 10.17% (1.86)
With adjustment for physical activity 10.35% (1.83)
Interleukin-6 (pg/ml) 1.78
Without adjustment for physical activity 9.22% (1.70)
With adjustment for physical activity 9.46% (1.68)
Homocysteine (mol/l) 0.843
Without adjustment for physical activity 8.61% (1.69)
With adjustment for physical activity 8.67% (1.67)ere show, for the first time, that higher levels of inflam- aatory markers and D-dimer are associated with smaller
alf muscle area and lower calf muscle density. Higher levels
f homocysteine were associated with reduced calf muscle
ensity, and elevated sVCAM-1 and IL-6 were associated
ith higher calf muscle percent fat. Most of these associa-
ions remained statistically significant after additional ad-
ustment for physical activity levels. These associations may
ontribute to previously established associations of elevated
iomarkers and functional impairment and functional de-
line in PAD.
Prior animal studies and studies in persons without PAD
uggest that inflammatory cytokines directly alter muscle
omeostasis by inhibiting repair after muscle tissue injury
ith Muscle
(n  251)
rtile 2 Quartile 3 Quartile 4
Trend
p Value
–1.86 1.86–3.82 3.82
8 (171) 5,666 (181) 5,108 (165) 0.004
6 (168) 5,684 (177) 5,121 (162) 0.005
–0.66 0.66–1.03 1.03
4 (176) 5,460 (176) 5,265 (189) 0.028
9 (175) 5,485 (174) 5,324 (188) 0.066
–1,041 1,041–1,331 1,331
9 (164) 5,642 (189) 5,295 (173) 0.035
9 (161) 5,644 (186) 5,368 (173) 0.110
–292 292–349 349
6 (178) 5,821 (180) 5,552 (177) 0.924
3 (176) 5,743 (179) 5,608 (175) 0.780
–2.60 2.60–4.54 4.54
6 (171) 5,878 (166) 4,885 (168) 0.001
0 (169) 5,837 (166) 4,940 (168) 0.001
–10.76 10.76–13.51 13.51
6 (188) 5,713 (175) 5,272 (183) 0.098
6 (185) 5,688 (172) 5,320 (181) 0.131
–1.86 1.86–3.82 3.82
% (1.72) 9.11% (1.82) 14.55% (1.66) 0.056
% (1.68) 8.95% (1.78) 14.55% (1.63) 0.078
–0.66 0.66–1.03 1.03
% (1.72) 10.73% (1.72) 12.60% (1.86) 0.278
% (1.71) 10.50% (1.70) 12.04% (1.85) 0.474
–1,041 1,041–1,331 1,331
% (1.63) 11.11% (1.88) 13.78% (1.72) 0.034
% (1.61) 11.09% (1.86) 13.08% (1.72) 0.106
–292 292–349 349
% (1.76) 9.20% (1.79) 11.76% (1.76) 0.748
% (1.74) 9.94% (1.79) 11.24% (1.75) 0.876
–2.60 2.60–4.54 4.54
% (1.74) 7.91% (1.70) 16.43% (1.71) 0.013
% (1.73) 8.34% (1.69) 15.87% (1.71) 0.025
–10.76 10.76–13.51 13.51
% (1.86) 9.03% (1.73) 14.54% (1.79) 0.065
% (1.83) 9.26% (1.70) 14.07% (1.77) 0.091
Continued on next pagescle51)
ers W
ease
Qua
0.89
5,84
5,84
0.47
5,81
5,75
843
5,53
5,51
247
5,36
5,40
1.78
5,62
5,64
0.843
5,55
5,53
0.89
8.88
8.88
0.47
8.38
8.88
843
9.81
10.00
247
12.01
11.64
1.78
9.80
9.65
0.843
11.62
11.80nd by promoting muscle proteolysis (2–5). These associa-
t
s
F
fl
o
m
t
(
i
r
l
a
d
d
h
a
o
m
a
g
a
a
p
C
D
a
p
le vasc
AP
*
l
903JACC Vol. 50, No. 9, 2007 McDermott et al.
August 28, 2007:897–905 Blood Markers and Calf Characteristicsions may explain associations of elevated CRP, IL-6, and
VCAM-1 with more adverse calf muscle characteristics.
urther, both D-dimer and homocysteine can induce in-
ammatory responses, and this may account for associations
f elevated D-dimer and homocysteine with more adverse
uscle characteristics (11–14,37). D-dimer promotes neu-
rophil and monocyte activation, including secretion of IL-6
11–14). Anhydrous thiolactone, derived from homocysteine,
s a potent inducer of inflammation (37). Alternatively, results
eported here may result from associations of higher biomarker
evels with greater atherosclerosis in the superficial femoral
rtery. In support of this latter hypothesis, previous study
ontinued
Table 1 Continued
Quartile 1
Calf muscle density (gm/cm3)
CRP (mg/l) 0.89
Without adjustment for physical activity 32.75 (0.62)
With adjustment for physical activity 32.65 (0.61)
D-dimer (g/ml) 0.47
Without adjustment for physical activity 33.51 (0.58)
With adjustment for physical activity 33.46 (0.58)
sVCAM-1 (ng/ml) 843
Without adjustment for physical activity 33.95 (0.59)
With adjustment for physical activity 33.81 (0.59)
sICAM-1 (ng/ml) 247
Without adjustment for physical activity 32.70 (0.65)
With adjustment for physical activity 32.64 (0.64)
Interleukin-6 (pg/ml) 1.78
Without adjustment for physical activity 33.74 (0.60)
With adjustment for physical activity 33.66 (0.60)
Homocysteine (mol/l) 0.843
Without adjustment for physical activity 33.16 (0.57)
With adjustment for physical activity 33.14 (0.57)
ata shown are means and standard errors. Data are adjusted for age, gender, race, cigarette
nkle-brachial index, total cholesterol, high-density lipoprotein cholesterol, and comorbidities. Data
hysical activity data.
CRP  C-reactive protein; sICAM-1  soluble intracellular adhesion molecule; sVCAM-1  solub
ssociations of Vascular Cellular Adhesion Molecule-1 and Homocyeripheral Arterial Disease, With and W thout Adj stment for Calf M
Table 2 Associations of Vascular Cellular Adhesion Molecule-1Peripheral Arterial Disease, With and Without Adjustm
sVCAM-1 (ng/ml)
Associations with plantarflexion strength (Model I) (newtons)
Model I with additional adjustment for calf muscle area (newtons)
Model I with additional adjustment for calf muscle percent fat (newtons)
Model I with additional adjustment for calf muscle density (newtons)
Model I with additional adjustment for all calf muscle characteristics (newtons)
Homocysteine (mol/l)
Associations with plantarflexion strength (Model I) (newtons)
Model I with additional adjustment for calf muscle area (newtons)
Model I with additional adjustment for calf muscle percent fat (newtons)
Model I with additional adjustment for calf muscle density (newtons)
Model I with additional adjustment for all calf muscle characteristics (newtons)
Data shown are means and standard errors. Model I adjusts for age, gender, race, body mass inde
eg symptoms, and the recruitment cohort.
sVCAM-1  soluble vascular cellular adhesion molecule 1.emonstrates that lower ABI values are associated indepen-
ently with more adverse calf muscle characteristics (38), and
igher levels of inflammation, D-dimer, and homocysteine are
ssociated with more severe atherosclerosis (6,39). Although
ur analyses adjusted for the ABI, the ABI is an imperfect
easure of the degree of lower extremity atherosclerosis.
Although associations of sVCAM-1, sICAM-1, D-dimer,
nd IL-6 with the 3 calf skeletal muscle characteristic were
enerally consistent for each of these biomarkers, not all
ssociations for the remaining biomarkers were consistent
cross the 3 calf measurements. Reasons for this latter
henomenon are unclear. However, determinants of each
rtile 2 Quartile 3 Quartile 4
Trend
p Value
–1.86 1.86–3.82 3.82
4 (0.61) 32.60 (0.64) 32.26 (0.59) 0.437
4 (0.60) 32.66 (0.63) 32.31 (0.58) 0.536
–0.66 0.66–1.03 1.03
5 (0.59) 32.55 (0.59) 30.63 (0.63) 0.001
2 (0.59) 32.61 (0.59) 30.77 (0.64) 0.002
–1,041 1,041–1,331 1,331
3 (0.54) 32.71 (0.62) 30.40 (0.57) 0.001
8 (0.54) 32.72 (0.62) 30.58 (0.57) 0.001
–292 292–349 349
8 (0.61) 33.18 (0.62) 32.67 (0.61) 0.844
0 (0.60) 32.94 (0.62) 32.84 (0.61) 0.720
–2.60 2.60–4.54 4.54
7 (0.62) 33.38 (0.60) 31.68 (0.61) 0.085
2 (0.61) 33.22 (0.60) 31.88 (0.61) 0.143
–10.76 10.76–13.51 13.51
6 (0.63) 33.72 (0.59) 30.59 (0.61) 0.015
1 (0.62) 33.66 (0.58) 30.73 (0.60) 0.021
ng, body mass index, leg symptoms, recruitment cohort (original WALCS vs. newly identified),
are only for participants with Caltrac (Muscle Dynamics Fitness Network, Inc., Rocklin, California)
ular cellular adhesion molecule; WALCS  Walking and Leg Circulation Study.
e With Plantarflexion Strength in Persons Withl Characteristics (n  403)*
Homocysteine With Plantarflexion Strength in Persons With
r Calf Muscle Characteristics (n  403)*
uartile 1 Quartile 2 Quartile 3 Quartile 4
Trend
p Value
857 857–1,075 1,075–1,361 1,361
.00 (21.89) 349.89 (20.19) 338.61 (21.95) 286.38 (23.75) 0.013
.59 (22.52) 347.64 (20.04) 329.42 (22.30) 294.94 (24.25) 0.036
.77 (22.84) 347.75 (20.31) 333.85 (22.63) 287.11 (24.42) 0.022
.33 (22.88) 342.86 (20.53) 335.81 (22.68) 293.31 (24.84) 0.049
.74 (22.65) 345.42 (20.43) 329.41 (22.55) 299.04 (24.81) 0.06
8.58 8.58–10.83 10.83–13.66 13.66
.12 (20.80) 323.62 (23.34) 337.82 (20.73) 309.76 (22.81) 0.05
.91 (21.47) 318.61 (23.14) 342.60 (21.05) 312.17 (23.46) 0.186
.97 (21.59) 319.54 (23.55) 338.93 (21.35) 305.70 (23.72) 0.074
.64 (21.51) 315.97 (23.61) 337.39 (21.26) 311.63 (24.01) 0.107
.14 (21.51) 316.72 (23.34) 341.82 (21.10) 316.01 (23.82) 0.235
ing, comorbidities, total cholesterol, high-density lipoprotein cholesterol, the ankle-brachial index,Qua
0.89
33.2
33.2
0.47
34.0
33.9
843
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Blood Markers and Calf Characteristics August 28, 2007:897–905alf muscle characteristic may be variable. Further study is
eeded to continue to identify biologic characteristics asso-
iated with calf muscle outcome in PAD.
This study is limited by its cross-sectional design. Asso-
iations reported here may not be causal and should not be
aken as definitive evidence that muscle characteristics are in
he causal pathway between elevated blood markers and
ower plantarflexion strength. Second, our measures did not
nclude CT assessment of skeletal muscle characteristics in
he upper extremities. We cannot rule out the possibility
hat elevated biomarker levels are also associated with more
dverse CT-assessed upper extremity muscle characteristics,
hich would suggest a systemic association of elevated
iomarkers with adverse skeletal muscle characteristics.
inally, we considered a p value 0.05 indicative of statis-
ical significance because this study is the first to assess
ssociations of blood markers with calf muscle characteris-
ics in persons with PAD, and we aimed to ensure that we
id not miss meaningful associations of blood markers with
alf muscle characteristics. However, a more conservative
pproach employing Bonferroni adjustment and a corre-
ponding p value0.005 criterion for statistical significance
ould have resulted in slightly fewer statistically significant
ndings.
onclusions
mong persons with PAD, increased levels of inflammatory
arkers, D-dimer, and homocysteine are associated with
dverse calf muscle characteristics in persons with PAD.
levated levels of inflammation and homocysteine are
ssociated with lower isometric plantar flexion strength.
rospective study is needed to identify mechanisms of
unctional decline in persons with PAD and to determine
hether blood marker-associated adverse calf muscle char-
cteristics are in the causal pathway of functional impair-
ent and decline in persons with PAD.
eprint requests and correspondence: Dr. Mary M. McDermott,
76 N. St. Clair, Suite 200, Chicago, Illinois 60611. E-mail:
dm608@northwestern.edu.
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